Difficulty: Medium
Average Score: 94%
Practice
A 22-year-old woman recently began medical treatment for a seizure disorder. She presents with dysuria; and a urine dipstick shows microhematuria but no leukocytes and no nitrites. A KUB X-ray shows calcifications in the renal pelvis, although she has neither personal nor family history of kidney stones. Which seizure medicine is she likely taking?
Correct answer
D
Rationale
In this scenario, the correct answer is D) Topiramate. Topiramate is associated with the development of kidney stones due to its carbonic anhydrase inhibitor properties, which can lead to metabolic acidosis and the formation of renal calculi. The presence of calcifications in the renal pelvis and microhematuria in the patient's urine dipstick results suggests this side effect.
A) Ethosuximide is typically used to treat absence seizures and is not associated with kidney stone formation. B) Phenobarbital is not known to cause kidney stones. C) Phenytoin is not associated with kidney stone formation either.
From an educational perspective, this question highlights the importance of understanding the side effects and adverse reactions associated with different medications, especially when managing chronic conditions like seizure disorders. It emphasizes the need for healthcare providers to monitor and educate patients on potential adverse effects to ensure timely intervention and management of complications. This case underscores the significance of pharmacovigilance and individualized patient care in clinical practice.
A) Ethosuximide is typically used to treat absence seizures and is not associated with kidney stone formation. B) Phenobarbital is not known to cause kidney stones. C) Phenytoin is not associated with kidney stone formation either.
From an educational perspective, this question highlights the importance of understanding the side effects and adverse reactions associated with different medications, especially when managing chronic conditions like seizure disorders. It emphasizes the need for healthcare providers to monitor and educate patients on potential adverse effects to ensure timely intervention and management of complications. This case underscores the significance of pharmacovigilance and individualized patient care in clinical practice.